ImmuCell Embarks on CEO Succession Planning Process
ImmuCell Corporation (Nasdaq: ICCC) has initiated a CEO succession planning process as current President and CEO Michael F. Brigham announces his intention to retire from full-time work by early 2026. Brigham, who joined ImmuCell in 1989 and has served as CEO since 2000, will turn 65 this fall.
The Board of Directors has already begun the search process, aiming to identify a new leader by year-end 2025. Brigham's financial responsibilities have been transferred to newly hired CFO Timothy C. Fiori. Brigham plans to remain with the company until a successor is found and will continue serving on the Board of Directors through his term ending in June 2026, with potential extended service subject to stockholder approval.
ImmuCell Corporation (Nasdaq: ICCC) ha avviato un processo di pianificazione della successione del CEO, poiché l'attuale Presidente e CEO Michael F. Brigham ha annunciato l'intenzione di ritirarsi dal lavoro a tempo pieno entro l'inizio del 2026. Brigham, che è entrato in ImmuCell nel 1989 e ha ricoperto il ruolo di CEO dal 2000, compirà 65 anni questo autunno.
Il Consiglio di Amministrazione ha già iniziato la ricerca del nuovo leader, con l'obiettivo di identificarlo entro la fine del 2025. Le responsabilità finanziarie di Brigham sono state trasferite al nuovo CFO Timothy C. Fiori. Brigham prevede di rimanere in azienda fino alla nomina del successore e continuerà a far parte del Consiglio di Amministrazione fino alla scadenza del suo mandato a giugno 2026, con possibile estensione soggetta all'approvazione degli azionisti.
ImmuCell Corporation (Nasdaq: ICCC) ha iniciado un proceso de planificación para la sucesión del CEO, ya que el actual Presidente y CEO Michael F. Brigham ha anunciado su intención de retirarse del trabajo a tiempo completo a principios de 2026. Brigham, quien se unió a ImmuCell en 1989 y ha sido CEO desde 2000, cumplirá 65 años este otoño.
La Junta Directiva ya ha comenzado el proceso de búsqueda, con el objetivo de identificar a un nuevo líder para finales de 2025. Las responsabilidades financieras de Brigham han sido transferidas al recién contratado CFO Timothy C. Fiori. Brigham planea permanecer en la empresa hasta que se encuentre un sucesor y continuará sirviendo en la Junta Directiva hasta el final de su mandato en junio de 2026, con posible extensión sujeta a la aprobación de los accionistas.
ImmuCell Corporation (나스닥: ICCC)는 현 사장 겸 CEO인 Michael F. Brigham이 2026년 초까지 전일제로 일하는 것을 은퇴할 의사를 밝힘에 따라 CEO 승계 계획 절차를 시작했습니다. 1989년에 ImmuCell에 합류해 2000년부터 CEO를 맡아온 Brigham은 이번 가을에 65세가 됩니다.
이사회는 이미 새 리더를 찾기 위한 절차를 시작했으며, 2025년 말까지 후임자를 선정하는 것을 목표로 하고 있습니다. Brigham의 재무 업무는 새로 채용된 CFO Timothy C. Fiori에게 이관되었습니다. Brigham은 후임자가 결정될 때까지 회사에 남아 있을 계획이며, 2026년 6월 임기 종료 시까지 이사회 활동을 계속할 예정이며, 주주 승인 시 임기 연장도 가능합니다.
ImmuCell Corporation (Nasdaq : ICCC) a lancé un processus de planification de la succession du PDG, alors que l'actuel président et PDG Michael F. Brigham annonce son intention de prendre sa retraite du travail à temps plein d'ici début 2026. Brigham, qui a rejoint ImmuCell en 1989 et occupe le poste de PDG depuis 2000, fêtera ses 65 ans cet automne.
Le conseil d'administration a déjà entamé la recherche d'un nouveau dirigeant, visant à identifier un successeur d'ici la fin de l'année 2025. Les responsabilités financières de Brigham ont été transférées au nouveau directeur financier Timothy C. Fiori. Brigham prévoit de rester dans l'entreprise jusqu'à ce qu'un successeur soit trouvé et continuera de siéger au conseil d'administration jusqu'à la fin de son mandat en juin 2026, avec une possible prolongation sous réserve de l'approbation des actionnaires.
ImmuCell Corporation (Nasdaq: ICCC) hat einen Nachfolgeplan für den CEO eingeleitet, da der derzeitige Präsident und CEO Michael F. Brigham seine Absicht angekündigt hat, sich bis Anfang 2026 aus der Vollzeitarbeit zurückzuziehen. Brigham, der 1989 zu ImmuCell kam und seit 2000 als CEO tätig ist, wird diesen Herbst 65 Jahre alt.
Der Vorstand hat bereits mit der Suche nach einem neuen Leiter begonnen und strebt an, bis Ende 2025 einen Nachfolger zu finden. Brighams finanzielle Verantwortlichkeiten wurden an den neu eingestellten CFO Timothy C. Fiori übertragen. Brigham plant, im Unternehmen zu bleiben, bis ein Nachfolger gefunden ist, und wird weiterhin im Vorstand bis zum Ende seiner Amtszeit im Juni 2026 tätig sein, mit möglicher Verlängerung vorbehaltlich der Zustimmung der Aktionäre.
- Orderly CEO succession planning process initiated well in advance
- Current CEO committed to smooth transition and continued Board service
- Recent CFO hire already completed, reducing transition risks
- Loss of long-tenured CEO with 35+ years of company experience
- Potential business disruption during leadership transition
- Uncertainty around future strategic direction under new leadership
PORTLAND, Maine, June 25, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has commenced a search for a successor in the position of President and CEO.
“I turn 65 this fall and have told my fellow Directors that I would like to retire from full-time work by early 2026,” said Michael F. Brigham, President and CEO. “I originally joined ImmuCell in 1989 and am very grateful to have had the opportunity to serve as the President and CEO of this growing Company since 2000.”
Mr. Brigham’s prior additional responsibilities as principal financial officer have been transferred to the Company’s recently hired Chief Financial Officer, Timothy C. Fiori. The Board of Directors’ search process for a new CEO is already underway with the expectation that Mr. Brigham would be available to help transition his CEO responsibilities as well.
“While there is no set deadline, our goal is to identify and select a top-notch candidate by around year-end, and I am fully committed to the search for a new leader,” continued Mr. Brigham. “I plan to remain until we find the optimal candidate, and I look forward to serving on our Board of Directors through my just elected term ending in June of 2026 and to continued Board service after that, subject to the vote of stockholders.”
About ImmuCell:
ImmuCell Corporation (Nasdaq: ICCC) creates scientifically proven and practical products to improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, which provides Immediate Immunity™ to newborn dairy and beef calves, and is developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter withdrawal label restrictions that hamper traditional mastitis antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.
| Contacts: | Michael F. Brigham, President and CEO Timothy C. Fiori, CFO ImmuCell Corporation (207) 878-2770 |
| Joe Diaz, Robert Blum and Joe Dorame Lytham Partners, LLC (602) 889-9700 |
Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement):
This Press Release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and will often include words such as “expects”, “may”, “anticipates”, “aims”, “intends”, “would”, “could”, “should”, “will”, “plans”, “believes”, “estimates”, “targets”, “projects”, “forecasts”, “seeks” and similar words and expressions. Such statements include, but are not limited to, any forward-looking statements relating to: our plans, goals and strategies for our business; projections of future operational performance; future demand for our products; the timing and outcome of pending or anticipated applications for regulatory approvals; and any other statements that are not historical facts. Such statements involve known and unknown risks and uncertainties that may cause the Company's actual results, financial or operational performance or achievements to be materially different from those expressed or implied by these forward-looking statements. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
FAQ
When is ImmuCell (ICCC) CEO Michael Brigham retiring?
Who will be the next CEO of ImmuCell Corporation?
How long has Michael Brigham been with ImmuCell (ICCC)?
Will Michael Brigham remain on ImmuCell's Board of Directors?
Who is ImmuCell's new CFO?
